Literature DB >> 1940356

Human T cell responses to gp63, a surface antigen of Leishmania.

D M Russo1, J M Burns, E M Carvalho, R J Armitage, K H Grabstein, L L Button, W R McMaster, S G Reed.   

Abstract

gp63, an abundant and conserved leishmania cell surface protein, has been implicated in the ability of these parasitic protozoa to infect macrophages in vitro and has shown potential as a protective immunogen in mice. However, little is known regarding human immune responses to this glycoprotein Ag. In this study, human T lymphocyte responses to Leishmania amazonensis native gp63 and to recombinant gp63 (rgp63) produced in Escherichia coli were evaluated in individuals with active or cured cutaneous, mucosal or visceral leishmaniasis. Both native and rgp63 elicited strong proliferative responses in all patients tested. In addition, IFN-gamma was produced in response to stimulation with both forms of the protein. T cell lines generated from PBMC by stimulation with native or rgp63 were phenotypically similar, and proliferated and produced IFN-gamma in response to stimulation with both forms of the molecule. These results suggest that gp63 is a strong T cell immunogen and that the recombinant and native forms can elicit the same type of T cell response from infected patients. In order to compare the immunogenic properties of these two forms of gp63, PBMC from naive (uninfected) donors were sensitized in vitro with native or rgp63. T cell lines generated against rgp63 proliferated in response to rgp63, but failed to proliferate in response to native gp63 or to promastigote lysate. Thus, rgp63 was effective in eliciting T cell responses from patients with active or cured leishmania infection, but did not effectively induce T cell responses under the conditions used.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1940356

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

1.  Virulent or avirulent (dhfr-ts-) Leishmania major elicit predominantly a type-1 cytokine response by human cells in vitro.

Authors:  C Brodskyn; S M Beverley; R G Titus
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

2.  Immunostimulatory cellular responses of cured Leishmania-infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of Leishmania donovani.

Authors:  R Garg; S K Gupta; P Tripathi; S Naik; S Sundar; A Dube
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

Review 3.  Leishmaniasis: current status of vaccine development.

Authors:  E Handman
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

4.  Glycosphingolipid antigens of Leishmania (Leishmania) amazonensis amastigotes identified by use of a monoclonal antibody.

Authors:  C L Barbiéri; S Giorgio; A J Merjan; E N Figueiredo
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

5.  Immunoblotting identifies an antigen recognized by anti gp63 in the immune complexes of Indian kala-azar patient sera.

Authors:  T Sanyal; D K Ghosh; D Sarkar
Journal:  Mol Cell Biochem       Date:  1994-01-12       Impact factor: 3.396

6.  Leishmaniasis Vaccine: Where are We Today?

Authors:  Lukasz Kedzierski
Journal:  J Glob Infect Dis       Date:  2010-05

7.  Leishmania pifanoi proteoglycolipid complex P8 induces macrophage cytokine production through Toll-like receptor 4.

Authors:  Shanta M Whitaker; Maria Colmenares; Karen Goldsmith Pestana; Diane McMahon-Pratt
Journal:  Infect Immun       Date:  2008-02-25       Impact factor: 3.441

8.  Kinesin motor domain of Leishmania donovani as a future vaccine candidate.

Authors:  Ayan Dey; Pawan Sharma; Naresh Singh Redhu; Sarman Singh
Journal:  Clin Vaccine Immunol       Date:  2008-03-19

9.  Human T-cell activation by 14- and 18-kilodalton nuclear proteins of Leishmania infantum.

Authors:  I Suffia; J F Quaranta; M C Eulalio; B Ferrua; P Marty; Y Le Fichoux; J Kubar
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

Review 10.  Leishmaniases of the New World: current concepts and implications for future research.

Authors:  G Grimaldi; R B Tesh
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.